Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 1, 2013, Pages 122-129

  Piao, Longzhu ^a   Li, Hong ^a   Teng, Lesheng ^a   Yung, Bryant C ^a   Sugimoto, Yasuro ^a   Brueggemeier, Robert W ^a,b   Lee, Robert J ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Human serum albumin (HSA); Lipid nanoparticles; RNA interference (RNAi)

Indexed keywords

BREAST CANCER; BREAST CANCER CELLS; CANCER CELLS; DOWN-REGULATION; FETAL BOVINE SERUM; HUMAN SERUM; HUMAN SERUM ALBUMINS; LIPID NANOPARTICLES; LOW TOXICITY; MCF-7 CELLS; MRNA EXPRESSION; NONVIRAL; PHARMACOKINETIC PROFILES; RNA INTERFERENCE; TARGETED DELIVERY; TUMOR MODELS;

CYTOLOGY; DISEASES; FLUORESCENCE; NANOPARTICLES; RNA; TUMORS;

CELLS;

HUMAN SERUM ALBUMIN; LIPOSOME; MESSENGER RNA; NANOPARTICLE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; FLUORESCENCE MICROSCOPY; GENE SILENCING; GENETIC REGULATION; IC 50; MEAN RESIDENCE TIME; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PLASMA HALF LIFE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROFLUOROMETRY; TUMOR VOLUME; TUMOR XENOGRAFT;

BASE SEQUENCE; BREAST NEOPLASMS; DNA PRIMERS; FEMALE; HUMANS; LIPID METABOLISM; MCF-7 CELLS; NANOPARTICLES; RNA, SMALL INTERFERING; SERUM ALBUMIN;

BOVINAE;

EID: 84871512864     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.03.008     Document Type: Article

References (32)

1. Akhtar S., Benter I.F. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007, 117:3623-3632.
2. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007, 6:443-453.
3. Kirchhoff F. Silencing HIV-1 in vivo. Cell 2008, 34:566-568.
4. Shim M.S., Kwon Y.J. Efficient and targeted delivery of siRNA in vivo. FEBS J 2010, 277:4814-4827.
5. Xia H., Mao Q., Paulson H.L., Davidson B.L. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002, 20:1006-1010.
6. Barton G.M., Medzhitov R. Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci U S A 2002, 99:14943-14945.
7. Tao W., Davide J.P., Cai M., Zhang G.J., South V.J., Matter A., et al. Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. Mol Ther 2010, 18:1657-1666.
8. Liu X., Howard K.A., Dong M., Andersen M.Ø., Rahbek U.L., Johnsen M.G., et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 2007, 28:1280-1288.
9. Werth S., Urban-Klein B., Dai L., Höbel S., Grzelinski M., Bakowsky U., et al. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J Control Release 2006, 112:257-270.
10. Simões S., Filipe A., Faneca H., Mano M., Penacho N., Düzgünes N., et al. Lipid nanoparticles for gene delivery. Expert Opin Drug Deliv 2005, 2:237-254.
11. Tseng Y.C., Huang L. Self-assembled lipid nanomedicines for siRNA tumor targeting. J Biomed Nanotechnol 2009, 5:351-363.
12. Musacchio T., Torchilin V.P. Recent developments in lipid-based pharmaceutical nanocarriers. Front Biosci 2011, 16:1388-1412.
13. Uchida E., Mizuguchi H., Ishii-Watabe A., Hayakawa T. Comparison of the efficiency and safety of non-viral vector mediated gene transfer into a wide range of human cells. Biol Pharm Bull 2002, 25:891-897.
14. Loisel S., Floch V., Le Gall C., Ferec C. Factors influencing the efficiency of lipoplexes mediated gene transfer in lung after intravenous administration. J Liposome Res 2001, 11:127-138.
15. Eliyahu H., Servel N., Domb A.J., Barenholz Y. Lipoplex induced hemagglutination: potential involvement in intravenous gene delivery. Gene Ther 2002, 9:850-858.
16. Kedmi R., Ben-Arie N., Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 2010, 31:6867-6875.
17. Tousignant J.D., Gates A.L., Ingram L.K., Johnson C.L., Nietupski J.B., Cheng S.H., et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid: plasmid DNA complexes in mice. Hum Gene Ther 2000, 11:2493-2513.
18. Masotti A., Mossa G., Cametti C., Ortaggi G., Bianco A., Grosso N.D., et al. Comparison of different commercially available cationic liposome-DNA lipoplexes: parameters influencing toxicity and transfection efficiency. Colloids Surf B Biointerfaces 2009, 68:136-144.
19. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010, 28:172-176.
20. Zhang S., Xu Y., Wang B., Qiao W., Liu D., Li Z. Cationic compounds used in lipoplexes and polyplexes for gene delivery. J Control Release 2004, 100:165-180.
21. Simberg D., Weisman S., Talmon Y., Barenholz Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst 2004, 21:257-317.
22. Ozpolat B., Sood A.K., Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 2010, 267:44-53.
23. Marty R., N'soukpoé-Kossi C.N., Charbonneau D.M., Kreplak L., Tajmir-Riahi H.A. Structural characterization of cationic lipid-tRNA complexes. Nucleic Acids Res 2009, 37:5197-5207.
24. Ding W., Izumisawa T., Hattori Y., Qi X., Kitamoto D., Maitani Y. Non-ionic surfactant modified cationic liposomes mediated gene transfection in vitro and in the mouse lung. Biol Pharm Bull 2009, 32:311-315.
25. Varma M.V., Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005, 25:445-453.
26. Zhang Z., Feng S.S. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006, 27:262-270.
27. Mu L., Feng S.S. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm Res 2003, 20:1864-1872.
28. Simoes S., Slepushkin V., Pires P., Gaspar R., Pedroso de Lima M.C., Duzgunes N. Human serum albumin enhances DNA transfection by lipoplexes and confers resistance to inhibition by serum. Biochim Biophys Acta 2000, 1463:459-469.
29. Faneca H., Simões S., Pedroso de Lima M.C. Association of albumin or protamine to lipoplexes: enhancement of transfection and resistance to serum. J Gene Med 2004, 6:681-692.
30. Sahin S., Selek H., Ponchel G., Ercan M.T., Sargon M., Hincal A.A., et al. Preparation, characterization and in vivo distribution of terbutaline sulfate loaded albumin microspheres. J Control Release 2002, 82:345-358.
31. Weecharangsan W., Yu B., Zheng Y., Liu S., Pang J.X., Lee L.J., et al. Efficient delivery of antisense oligodeoxyribonucleotide g3139 by human serum albumin-coated liposomes. Mol Pharm 2009, 6:1848-1855.
32. Acharyaa S., Sahoo S.K. PLGA nanoparticles containing various anticancer agents and tumor delivery by EPR effect. Adv Drug Deliv Rev 2011, 63:170-183.